Kala Bio (KALA) Operating Expenses (2016 - 2026)
Kala Bio (KALA) posted Operating Expenses of $1.8 million for Q1 2026, down 82.38% sequentially from $10.2 million in Q4 2025, and down 83.11% YoY from $10.7 million in Q1 2025.
Kala Bio (KALA) Operating Expenses (2016 - 2026) Analysis & Trends
Kala Bio has reported Operating Expenses for 11 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Operating Expenses fell 83.11% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.3 million (down 23.73% YoY) and the FY2025 annual result came in at $39.2 million, down 4.45% from the prior year.
- Operating Expenses retreated to $1.8 million in Q1 2026 per KALA's latest filing, from $10.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $32.3 million in Q1 2022 and troughed at $1.8 million in Q1 2026.
- A 5-year average of $12.2 million and a median of $10.2 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2025 and 2026: Operating Expenses gained 14.82% in 2025, then sank 83.11% in 2026.
- Over 5 years, Operating Expenses stood at $10.3 million in 2022, then dropped by 6.17% to $9.6 million in 2023, then dropped by 1.66% to $9.5 million in 2024, then gained by 8.1% to $10.2 million in 2025, then slumped by 82.38% to $1.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $1.8 million, $10.2 million, and $7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | 1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2025 | 10.23 Mn |
| Sep 30, 2025 | 7.24 Mn |
| Jun 30, 2025 | 11.03 Mn |
| Mar 31, 2025 | 10.67 Mn |
| Dec 31, 2024 | 9.46 Mn |
| Sep 30, 2024 | 9.99 Mn |
| Jun 30, 2024 | 9.61 Mn |
| Mar 31, 2024 | 11.93 Mn |
| Dec 31, 2023 | 9.62 Mn |
| Sep 30, 2023 | 8.76 Mn |
| Jun 30, 2023 | 9.60 Mn |
| Mar 31, 2023 | 11.68 Mn |
| Dec 31, 2022 | 10.25 Mn |
| Sep 30, 2022 | 14.99 Mn |
| Jun 30, 2022 | 28.07 Mn |
| Mar 31, 2022 | 32.29 Mn |
| Dec 31, 2021 | 48.67 Mn |
| Sep 30, 2021 | 29.14 Mn |
| Jun 30, 2021 | 32.10 Mn |